FDA Brief

Warning letters Drugs

FDA warning letter to

Coco's Holistic Specialties & Apothecary

High riskIssued Jan 4, 2021Posted Jan 5, 2021Center for Drug Evaluation and Research | CDER

FDA warned Coco's Holistic Specialties & Apothecary that its 4-Thieves teas are unapproved, misbranded drugs sold with COVID-19 treatment claims.

What happened

FDA reviewed the company's website on November 19, 2020, and the Federal Trade Commission (FTC) reviewed it on December 17, 2020; FDA also reviewed the company's Facebook and Twitter pages, which send buyers to the site. The site offered 4-Thieves Florida Tea Concentrate and 4-Thieves Florida Tea Powder with statements calling the products an "anti-COVID herbal inoculation" that is "safe & effective" and that the owner used to treat eight women for COVID-19-like symptoms. FDA concluded the products are unapproved new drugs and are misbranded.

What FDA found

  1. The company sells teas meant to prevent or treat COVID-19 without FDA approval, which makes them unapproved new drugs.

    Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The products are misbranded because their labeling makes disease claims without the required approved drug information.

    Section 502 of the FD&C Act, 21 U.S.C. § 352
  3. Moving these products in interstate commerce is prohibited.

    Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. Website and social media posts state the tea is an antiviral inoculation effective against COVID-19 and safe for all ages, which establishes the intended use and misrepresents the product as safe and effective.

  5. Advertising that a product prevents, treats, or cures a disease without competent and reliable scientific evidence is unlawful, and no such study exists for COVID-19 for this product.

    FTC Act, 15 U.S.C. 41 et seq.

What FDA wants

FDA asks the company to immediately stop selling these products for COVID-19 and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov describing the specific steps taken and how recurrence will be prevented, with supporting documents. The FTC separately asks for an email within 48 hours to Richard Cleland describing the actions taken on the advertising claims.

Who should pay attention

  • herbal and tea brands that make health or antiviral claims
  • small e-commerce and social media sellers of supplements
  • marketers and copywriters writing disease-related product claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk